DEDICATED EXPERTS ADVANCING PARKIN THERAPIES TO THE CLINIC
FinsnoBio's small molecule therapeutic strategy is built on decades of research and a relentless focus on the highly-validated Parkin-mitophagy pathway.
While mitochondria are found in every cell, FinsnoBio’s initial therapeutic focus is on oncology and Parkinson’s Disease (PD), where overwhelming data has validated Parkin activity for disease mitigation.
Our pioneering oncology molecules are making rapid progress toward IND and human proof-of-concept. Furthermore, select compound series from our growing chemical library are being rapidly developed for CNS indications. Beyond these leading indications, Parkin’s broad horizon of therapeutic potential is clearly within view.
Fueling this entire effort, FinsnoBio’s drug discovery platform combines the world’s most advanced technologies with our team’s unmatched expertise. Fragment-Based X-Ray Crystallography, AI-Driven In Silico Screening, cryo-EM, and traditional high-throughput compound screening work in concert to capture the full range of therapeutic possibilities of this dynamic and powerful protein.
Oncology: Our first-in-class, peripherally bioavailable compounds are advancing to IND for specific oncology indications based on the mechanism of action of our molecules. Parkin enzyme activation directs degradation of a clinically-validated oncogene arresting tumor cell growth as both a monotherapy, as well as in combination with established chemotherapeutic agents. With the guidance of the world's leading experts FinsnoBio's path to clinical trials is clear.
Neurology and PD: FinsnoBio is utilizing our highly experienced drug development experts to merge the chemistry of peripherally available Parkin activators with optimized blood brain barrier penetration. We are also expanding the Parkin-activator chemical universe with new chemical entities by leveraging our discovery platform using CNS-focused libraries as starting points.
Far-Reaching Applications of Mitochondrial Health Stimulation: Because mitochondria are essential for every cell in the human body, dysfunction in this pathway can affect human health in many diverse ways. We are leveraging our understanding of Parkin activation toward peripheral diseases with a pathology that can be mitigated by stimulation of mitochondrial repair.
FinsnoBio’s Drug Discovery Platform: Parkin’s ability to repair damaged mitochondria has the potential for profound impact across a wide range of human disease, and we are pulling out all the stops in our efforts to identify potent therapeutics. We have carefully selected multiple new compound discovery paradigms that incorporate our unparalleled experience in identifying ligands for this target. Our corporate partnerships unite FinsnoBio’s deep target knowledge, with cutting-edge technologies ranging from AI-driven computational analysis and X-ray Crystallography to novel biophysical readouts of enzyme activation. These efforts will fuel our team’s pipeline with new tools and technology as we generate the new frontiers in Parkin chemistry.
Proteolysis-Targeting Chimera: All of our Parkin-activating small molecules are also powerful tools in the development of new Targeted Protein Degradation starting points. The rapid advancement of proteolysis-targeting chimera (registered as PROTAC® by Arvinas Operations, Inc.) to the clinic has demonstrated the broad applicability of E3 ligase small molecule binding compounds as an exciting new application for E3 ligase small molecule binding compounds. Our deep understanding of our lead molecules that activate Parkin for oncology provide a platform for Degrader design and testing. In addition, our new compound discovery efforts will identify additional starting points for peripheral and CNS-focused Degrader development.
Our mission is clear, and our team is expanding quickly. As we advance our current molecules, and discover new chemistry to enhance mitochondrial health, FinsnoBio’s work will expand and define the new frontiers of small molecule Parkin therapeutics.